March 5, 2020 / 12:12 PM / 25 days ago

BRIEF-Can-Fite Updates On Clinical Milestone For Its Phase III Rheumatoid Arthritis Study With Piclidenoson; Drugs Combating Rheumatoid Arthritis Are Currently Introduced For The Treatment Of The Coronavirus

March 5 (Reuters) - Can Fite Biopharma Ltd:

* CAN-FITE UPDATES ON CLINICAL MILESTONE FOR ITS PHASE III RHEUMATOID ARTHRITIS STUDY WITH PICLIDENOSON; DRUGS COMBATING RHEUMATOID ARTHRITIS ARE CURRENTLY INTRODUCED FOR THE TREATMENT OF THE CORONAVIRUS

* CAN FITE BIOPHARMA LTD - DATA FROM INTERIM ANALYSIS OF PICLIDENOSON IN ITS PHASE III CLINICAL STUDY IS EXPECTED TO BE RELEASED DURING Q4 2020

* CAN FITE BIOPHARMA LTD - NOW EXPLORING A COLLABORATION TO LOOK AT EFFECT OF PICLIDENOSON AGAINST CORONAVIRUS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below